Overview

Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Acne Patients

Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The combined bacteriostatic and immunomodulatory effects of erythromycin and clindamycin will be explored. Treatment effects will be extensively characterized by conventional methods including lesion counts, global assessment scales and visual grading as well as state-of-the-art methodology, including multi-modal photo analysis, perfusion by laser speckle contrast imaging, analysis of local skin surface, biopsy biomarkers and skin microbiota. This extensive response profiling, combined with the mechanistic insights from concurrent in vitro and in vivo studies in healthy volunteer challenges, will increase the understanding of erythromycin's and clindamycin's effects in acne vulgaris.
Phase:
Phase 4
Details
Lead Sponsor:
Centre for Human Drug Research, Netherlands
Collaborators:
Cutanea Life Sciences, Inc.
Maruho Co., Ltd.
Treatments:
Anti-Inflammatory Agents
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Erythromycin
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Ethanol
Pharmaceutical Solutions